comparemela.com

Latest Breaking News On - District of maryland southern division - Page 1 : comparemela.com

Construction Company Lawsuit Targets Its Retirement Plan Providers

EBS Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors or June 18, 2021 Deadline in Securities Fraud Class Action Lawsuit

EBS Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors or June 18, 2021 Deadline in Securities Fraud Class Action Lawsuit
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Emergent BioSolutions Inc of Deadline in Securities Fraud Class Action Lawsuit

Home / Top News / Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Emergent BioSolutions Inc. of Deadline in Securities Fraud Class Action Lawsuit Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Emergent BioSolutions Inc. of Deadline in Securities Fraud Class Action Lawsuit RADNOR, Pa., June 03, 2021 (GLOBE NEWSWIRE) The law firm of Kessler Topaz Meltzer & Check, LLP announces that the firm has filed a securities fraud class action against Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”) on behalf of investors who purchased or acquired Emergent common stock between April 24, 2020, and April 16, 2021, inclusive (the “Class Period”). This action, captioned Roth v. Emergent BioSolutions Inc., et al., Case No. 1:21-cv-01189-CCB (the “

Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc

The Roth Action alleges that, throughout the Class Period, the defendants failed to disclose that: (1) Emergent s Baltimore facility had a history of manufacturing issues increasing the likelihood for massive contaminations; (2) the Baltimore facility had received a series of Food and Drug Administration ( FDA ) citations as a result of these contamination risks and quality control issues; (3) Emergent had been forced to discard millions of doses of COVID-19 vaccines after workers at the facility deviated from manufacturing standards; and (4) as a result of the foregoing, the defendants public statements about Emergent s ability and capacity to mass manufacture multiple COVID-19 vaccines at its Baltimore facility were materially false and/or misleading and/or lacked a reasonable basis.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.